Khadija Rouaz El Hajoui

Ms. Khadija Rouaz El Hajoui

University of Barcelona, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Khadija Rouaz El HajouiKhadija Rouaz El Hajoui
Khadija Rouaz El Hajoui
Blanca Chiclana-RodríguezBlanca Chiclana-Rodríguez
Blanca Chiclana-Rodríguez
Anna Nardi RicartAnna Nardi Ricart
Anna Nardi Ricart
MSMarc Suñé-Pou
Marc Suñé-Pou
DMDébora Mercade
Débora Mercade
Encarna Garcia-MontoyaEncarna Garcia-Montoya
Encarna Garcia-Montoya
This theoretical study seeks to critically review the use of excipients in the paediatric population. This study is based on the rules and recommendations of European and American drug regulatory agencies. On the one hand, this review describes the most frequent excipients used in paediatric medicine formulations, identifying the compounds that scientific literature has marked as potentially harmful regarding the side effects generated after exposure. On the other hand, this review also highlights the importance of carrying out safety -checks on the excipients, which, in most cases, are linked to toxicity studies. An excipient in the compilation of paediatric population databases is expected to target safety and toxicity, as in the STEP database. Finally, a promising pharmaceutical form for child population, ODT (Orally Disintegrating Tablets), will be studied.

6 December 2025 in Information
Verified
Journal Article
Open access
PDF file
MRMiquel Romero-Obon
Miquel Romero-Obon
Khadija Rouaz El HajouiKhadija Rouaz El Hajoui
Khadija Rouaz El Hajoui
VSVirginia Sancho-Ochoa
Virginia Sancho-Ochoa
RVRonny Vargas
Ronny Vargas
Pilar Pérez-LozanoPilar Pérez-Lozano
Pilar Pérez-Lozano
Encarna Garcia-MontoyaEncarna Garcia-Montoya
Encarna Garcia-Montoya
The pharmaceutical industry’s pursuit of enhanced product quality, regulatory compliance, and operational efficiency has catalyzed the integration of Artificial Intelligence (AI) into Ongoing Process Verification (OPV) frameworks. This comprehensive review examines the synergistic application of Human-in-the-Loop (HITL) AI systems within OPV, contextualized by the evolving regulatory landscape, particularly the newly introduced Annex 22 of the European Union Good Manufacturing Practices (EU-GMP). The review delineates the sector’s strategic shift from traditional validation models toward dynamic, data-driven approaches that leverage AI for real-time monitoring, predictive analytics, and proactive process control. Central to this transformation is the HITL paradigm, which ensures that human expertise remains embedded in critical decision-making loops, thereby safeguarding patient safety, product quality, data integrity, and ethical responsibility. Annex 22 explicitly mandates deterministic behavior, traceability, and explainability for AI models used in GMP-critical applications, excluding adaptive and probabilistic systems from such contexts. The document also reinforces the necessity of multidisciplinary governance, rigorous validation protocols, and risk-based oversight throughout the AI lifecycle. This paper synthesizes current industry practices, regulatory expectations, and technological capabilities, offering a structured framework for compliant AI deployment in OPV. By aligning AI implementation with Annex 22 principles and existing GMP frameworks (e.g., Annex 11 and ICH Q9), the pharmaceutical sector can harness AI’s transformative potential while maintaining robust regulatory compliance. The review concludes with actionable recommendations for integrating HITL AI into OPV strategies, fostering a resilient, transparent, ethical, and future-ready manufacturing ecosystem.

25 December 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Blanca Chiclana-RodríguezBlanca Chiclana-Rodríguez
Blanca Chiclana-Rodríguez
Encarna Garcia-MontoyaEncarna Garcia-Montoya
Encarna Garcia-Montoya
Miquel RomeroMiquel Romero
Miquel Romero
Khadija Rouaz El HajouiKhadija Rouaz El Hajoui
Khadija Rouaz El Hajoui
Anna Nardi RicartAnna Nardi Ricart
Anna Nardi Ricart
Pilar Pérez-LozanoPilar Pérez-Lozano
Pilar Pérez-Lozano
Carvedilol (CARV) is a blocker of α- and β- adrenergic receptors, used as an “off-label” treatment for cardiovascular diseases in pediatrics. Currently, there is no marketed pediatric-appropriate CARV liquid formulation, so its development is necessary. Palatability (appreciation of smell, taste, and aftertaste) is a key aspect to be considered during the development of pediatric formulations since only formulations with good palatability also have adequate acceptability in this population. Consequently, the aim of this research was to assess the palatability and acceptability of different CARV formulations using an in vivo taste assessment (ID Number PR103/22) in order to select the highest palatability-rated CARV formulation. The preparation of CARV formulations was based on a reference 1 mg/mL CARV solution, which contains malic acid as a solubilizing agent. Subsequently, sucralose and flavoring agents were added and mixed until complete dissolution to the corresponding formulations. Adult volunteers participated in this study and evaluated the taste and odor of various CARV formulations through a questionnaire and a sensory test. The mean palatability score, measured on a 10-point scale, increased from 1.60 for the unflavored control to 7.65 for the highest-rated flavored formulation. Moreover, the bitterness of the optimized CARV formulation was reduced from 66.67% to 17.86%, and the taste pleasantness was increased from 25/100 to 73/100. This optimized CARV formulation contains a sweetening agent, sucralose, in addition to two flavoring agents at appropriate concentrations for pediatrics. Furthermore, the physicochemical and microbiological stability of the optimized CARV formulation were evaluated for 6 months at 25, 30, and 40 °C, in addition to in-use stability for 15 days at 25 °C, whose results were confirmed. Thus, we successfully developed a palatable CARV liquid solution that contains excipients appropriate for pediatrics and is stable under the studied conditions.

5 September 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Blanca Chiclana-RodríguezBlanca Chiclana-Rodríguez
Blanca Chiclana-Rodríguez
Encarna Garcia-MontoyaEncarna Garcia-Montoya
Encarna Garcia-Montoya
Khadija Rouaz El HajouiKhadija Rouaz El Hajoui
Khadija Rouaz El Hajoui
Miquel RomeroMiquel Romero
Miquel Romero
Anna Nardi RicartAnna Nardi Ricart
Anna Nardi Ricart
Pilar Pérez-LozanoPilar Pérez-Lozano
Pilar Pérez-Lozano
Carvedilol (CARV) is an ‘off-label’ β-blocker drug to treat cardiovascular diseases in children. Since CARV is nearly insoluble in water, only CARV solid forms are commercialized. Usually, CARV tablets are manipulated to prepare an extemporaneous liquid formulation for children in hospitals. We studied CARV to improve its aqueous solubility and develop an oral solution. In this study, we assessed the solubility and preliminary stability of CARV in different pH media. Using malic acid as a solubility enhancer had satisfactory results. We studied the chemical, physical, and microbiological stability of 1 mg/mL CARV–malic acid solution. A design of experiment (DoE) was used to optimize the CARV solution’s preparation parameters. A 1 mg/mL CARV solution containing malic acid was stable for up to 12 months at 25 °C and 30 °C and 6 months at 40 °C. An equation associating malic acid with CARV concentrations was obtained using DoE. Microbiological data showed that the use of methylparaben was not necessary for this period of time. We successfully developed an aqueous CARV solution suitable for paediatrics and proven to be stable over a 12-month period.

8 May 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RCRicard Canadell-Heredia
Ricard Canadell-Heredia
Khadija Rouaz El HajouiKhadija Rouaz El Hajoui
Khadija Rouaz El Hajoui
NFNatalia Franco-Piedrahita
Natalia Franco-Piedrahita
Pilar Pérez-LozanoPilar Pérez-Lozano
Pilar Pérez-Lozano
MSMarc Suñé-Pou
Marc Suñé-Pou
Encarna Garcia-MontoyaEncarna Garcia-Montoya
Encarna Garcia-Montoya
Background/Objectives: Carbamazepine is widely used as a first-line treatment for pediatric patients with benign epilepsy. However, most commercial formulations have doses of 100 mg or higher, limiting their suitability for pediatric use. The aim of this study was to develop mini orally disintegrating tablets (ODTs) containing 50 mg of carbamazepine, utilizing direct compression technology, specifically tailored to meet the unique needs of pediatric patients. Methods: The development was carried out following a Quality by Design (QbD) approach, beginning with preformulation studies using the SeDeM expert system. Various co-processed excipients (PROSOLV® ODT and PARTECK® ODT) and non-co-processed excipients (L-HPC LH11 and L-HPC NBD-022) were evaluated. Additionally, modifications to the radius parameter of the SeDeM expert system were investigated to improve formulation design. Results: Optimized Formulations 13 and 14 achieved disintegration times below 1 min, hardness values between 25 and 60 N, and friability under 1%, fulfilling the predefined Critical Quality Attributes (CQAs). Tablets were successfully produced with a diameter of 5 mm and a weight below 100 mg. Moreover, reducing the SeDeM incidence radius from 5.0 to values between 4.0 and 3.5 proved viable, enabling the inclusion of excipients previously considered unsuitable and broadening formulation options without compromising quality. Conclusions: This study demonstrates the feasibility of producing small, fast-disintegrating, and mechanically robust 50 mg carbamazepine ODTs tailored for pediatric patients. It also validates the adjustment of SeDeM parameters as an effective strategy to expand excipient selection and enhance formulation flexibility in pediatric drug development.

5 August 2024 in Children
Verified
Journal Article
Open access
PDF file
Khadija Rouaz El HajouiKhadija Rouaz El Hajoui
Khadija Rouaz El Hajoui
Encarna Garcia-MontoyaEncarna Garcia-Montoya
Encarna Garcia-Montoya
MSMarc Suñé-Pou
Marc Suñé-Pou
Josep Suñé-NegreJosep Suñé-Negre
Josep Suñé-Negre
Pilar Pérez-LozanoPilar Pérez-Lozano
Pilar Pérez-Lozano
Objectives: This study addresses a critical need in pediatric pharmacotherapy by focusing on the development of an enteric formulation of omeprazole for pediatric use. Omeprazole, a widely used proton pump inhibitor, is essential for treating various gastrointestinal disorders in children. The main objective is to design a compounding formula that can be prepared in hospital pharmacy services without the need for industrial equipment, which is often unavailable in these settings. Methods: The research applied different galenic strategies to overcome the challenges of omeprazole’s instability in acidic environments and its complex pharmacokinetic and physicochemical properties. The experiments were conducted sequentially, employing salting out, ionic gelation, and matrix granulation strategies. Based on the results obtained, the control conditions and parameters for the various trials were established. Results: Among the techniques used, wet granulation proved to be the most promising, achieving a gastro-resistance level of 44%. In contrast, the ionic gelation and salting-out techniques did not yield satisfactory results. Conclusions: The findings of this study underscore the need to adopt alternative formulation strategies to ensure the stability of omeprazole. This goal requires a multidisciplinary approach and continuous effort to design omeprazole formulations that meet quality standards and appropriate gastro-resistance requirements.